Skip to content
Clinical Trials – home
Not yet recruitingRare disease

A Study to Assess Effectiveness of IPN60340 with Drug Combination in Adults with Newly Diagnosed Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Verified siteFast replyRegistered drug
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

Acute Myeloid Leukemia is a fast‑growing blood cancer that often affects older adults or people with other health problems, making them unable to receive strong, high‑dose chemotherapy. The trial tests a new medicine called IPN60340, which is a laboratory‑made protein that attaches to a specific target on cancer cells, given through an IV line. All participants also receive two standard drugs: the injectable medicine azacitidine, which helps cancer cells mature and die, and the oral pill venetoclax, which blocks a protein that cancer cells need to survive. For comparison, some participants receive a harmless fluid called placebo instead of the new protein while still taking the two standard drugs.

The purpose of the study is to find out whether adding the new protein to the usual drug combination improves treatment results. Participants are randomly assigned to one of the two groups and receive the assigned medicines in repeated cycles over several months, with regular clinic visits for infusions, pill dispensing, and injections. Blood tests and other simple checks are done at each visit to see how the disease is responding and to watch for any side effects.

Researchers will look at how many people achieve complete remission (no signs of leukemia in the blood), how long remission lasts, overall survival time, and whether patients can go long periods without needing blood or platelet transfusions (transfusion independence). They will also record any side effects and ask participants to fill out short questionnaires about their daily well‑being. This information helps determine if the new treatment offers a meaningful benefit over the standard approach.

The research process

The trial runs in 9 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Enrollment and Randomization

    After agreeing to join the study, you are assigned to one of two groups. One group receives IPN60340 together with azacitidine and venetoclax, and the other group receives a placebo together with azacitidine and venetoclax. Randomization makes the assignment unpredictable and ensures fairness.

  2. Step 2

    Baseline Assessments

    Before any medication is given, doctors perform blood tests, a physical examination, and other checks to confirm the diagnosis of acute myeloid leukaemia and to verify that you meet all eligibility criteria.

  3. Step 3

    First Intravenous Infusion

    On the first day of treatment you receive an intravenous (IV) infusion. If you are in the active group, the infusion contains IPN60340; if you are in the control group, the infusion contains saline as a placebo. The infusion is delivered through a vein over a period defined by the study protocol.

  4. Step 4

    Daily Oral Venetoclax

    Starting on the same day, you take a tablet of venetoclax by mouth at a dose of 400 mg each day. The tablet is swallowed with water and taken at the same time each day for the entire treatment period.

  5. Step 5

    Subcutaneous Azacitidine Injections

    You also receive an injection of azacitidine under the skin (subcutaneous injection) at a dose of 75 mg per square meter of body surface area. The injection schedule follows the study protocol, typically once per day for a set number of days in each treatment cycle.

  6. Step 6

    Ongoing Monitoring Visits

    Throughout the treatment you attend regular clinic visits. At each visit blood samples are taken and your doctor checks for side effects and evaluates how the disease is responding. These visits occur at intervals specified by the study, often at the start of each new cycle.

  7. Step 7

    Repeating Treatment Cycles

    The combination of the IV infusion, daily oral venetoclax, and subcutaneous azacitidine is repeated for multiple cycles as directed by the study. The exact number of cycles is determined by the investigators based on your response and tolerance to the medicines.

  8. Step 8

    End‑of‑Treatment Assessment

    When the planned treatment period ends, you undergo a comprehensive assessment to determine whether you have achieved complete remission (no detectable disease) or another level of response. Additional tests may include a bone‑marrow examination.

  9. Step 9

    Follow‑Up Period

    After treatment stops, you continue to be followed for several months or years. Follow‑up visits include blood tests and health evaluations to monitor long‑term outcomes such as survival, disease recurrence, and quality of life.

Who can join the trial?

7 criteria

  • Be at least 18 years old when you sign the study paperwork.
  • Have a new diagnosis of Acute Myeloid Leukaemia (AML) that meets the World Health Organization (WHO) 2022 guidelines.
  • Have an ECOG performance status score of 1‑2 if you are 75 years or older, or a score of 1‑3 if you are younger than 75. (The ECOG score measures how well you can perform everyday activities, with lower numbers meaning better function.)
  • Be considered unable to receive intensive chemotherapy because of your age or other health problems (called comorbidities). (Intensive chemotherapy means very strong cancer‑killing medicines that are not suitable for some patients.)
  • Have enough healthy organ function (such as heart, liver, and kidneys) as required by the study protocol.
  • Use a method of contraception (birth control) yourself or with your partner, following the rules that apply in your area for clinical trial participants.
  • Provide a signed informed consent form, agreeing to follow all study requirements and restrictions.

Who cannot join the trial?

20 criteria

  • Having a current diagnosis of Acute promyelocytic leukemia (APL), a specific type of blood cancer, excludes you.
  • Having active or uncontrolled central nervous system (CNS) leukemia, meaning the leukemia has spread to the brain or spinal cord, excludes you.
  • Having any γ9δ2TC neoplasm, a rare cancer of certain immune cells, excludes you.
  • Having severe bacterial, fungal, viral, or parasitic infections that are not under control and require strong treatment (not just preventive medicines) excludes you.
  • Having uncontrolled human immunodeficiency virus (HIV) disease excludes you; only well‑controlled HIV is allowed.
  • Testing positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) at screening or within the three months before randomization excludes you.
  • Testing positive for hepatitis C antibody without a confirming negative hepatitis C RNA test (which shows no active virus) excludes you.
  • Using strong or moderate cytochrome P450 (CYP)3A inducers (medications that speed up drug metabolism) within seven days before starting the study drug excludes you.
  • Being unable to swallow capsules or tablets excludes you.
  • Having previously received any hypomethylating agents, chemotherapy, BCL2 inhibitors, other clinical trial treatments, cellular therapy, or an allogenic hematopoietic cell transplantation (HCT) for myelodysplastic syndromes (MDS) excludes you.
  • Taking systemic corticosteroids higher than 10 mg per day of prednisone (or an equivalent dose) or other strong immune‑suppressing medicines within five drug half‑lives before the first dose, or needing such medicines during the study, excludes you.
  • Having an allergy or sensitivity to the study drugs, their ingredients, or any related medication that the investigator believes makes participation unsafe excludes you.
  • Having a history of myeloproliferative neoplasms (MPN) such as primary myelofibrosis, essential thrombocythemia, polycythemia vera, chronic myeloid leukemia, or MDS/MPN, or having treatment‑related AML, excludes you.
  • Having another cancer diagnosed within the past two years excludes you.
  • Having disease that is progressing very quickly, as judged by the doctor, which might prevent you from receiving the study treatment, excludes you.
  • Having significant or uncontrolled heart problems within six months before the first study day excludes you.
  • Having a white blood cell count higher than 25 × 10⁹/L (unless it is lowered before starting treatment) excludes you.
  • Having severe liver disease (classified as Child‑Pugh C, which indicates very poor liver function) excludes you.
  • Having had major surgery within four weeks before the first study day, or planning such surgery during the study period, excludes you.
  • Having any gastrointestinal disorder or malabsorption condition that could prevent proper absorption of the study medication (venetoclax) excludes you.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • IPN60340

    is an experimental, human‑engineered antibody that is given through an IV drip. It is designed to attach to a specific target called the butyrophilin‑3A receptor on certain immune cells. In this trial, researchers are testing whether adding this antibody to standard treatment can help the body fight newly diagnosed acute myeloid leukemia more effectively.

  • Azacitidine

    is a chemotherapy medicine that is injected under the skin. It works by changing the DNA inside leukemia cells, which can stop the cells from growing and help them die. In the study, azacitidine is part of the standard background therapy that all participants receive.

  • Venetoclax

    is a pill taken by mouth. It blocks a protein called BCL‑2 that many cancer cells use to avoid dying. By inhibiting this protein, venetoclax helps the body’s own mechanisms kill the leukemia cells. In the trial, it is also given to all participants as part of the standard background treatment alongside azacitidine.

What is already known about the treatment

  • IPN60340

    This drug is given by IV infusion as a clear solution and is a human‑engineered IgG1 monoclonal antibody that targets the butyrophilin‑3A receptor on leukemia cells. It is an experimental orphan drug currently being studied in clinical trials for acute myeloid leukemia (AML). The antibody works by marking the cancer cells so the immune system can recognize and destroy them. It belongs to the class of monoclonal antibody immunotherapies.

  • Venetoclax

    Venetoclax is taken orally as a tablet, usually 400 mg per day, and is an approved medicine for AML and chronic lymphocytic leukemia. It is used in this study together with azacitidine to treat patients who cannot receive intensive chemotherapy. The drug blocks the BCL‑2 protein, which helps cancer cells survive, thereby allowing the cells to die. It is classified as a BCL‑2 inhibitor and a targeted anticancer therapy.

  • Azacitidine

    Azacitidine is administered by subcutaneous injection at a dose of 75 mg/m² and is an approved treatment for AML and related blood disorders. In the trial it is combined with venetoclax and the test drug for patients unsuitable for intensive chemotherapy. It works by inserting into DNA and interfering with the abnormal growth of cancer cells, helping them to die or stop dividing. This medication is a hypomethylating antineoplastic agent.

  • Saline

    Saline is given intravenously as a sterile salt‑water solution and serves as the placebo in this study. It has no active therapeutic effect and is used only to compare the effects of the active drugs. The solution simply provides a neutral fluid for infusion. It is classified as an isotonic solution and a placebo.

Investigated diseases

Acute Myeloid Leukemia (AML) - Acute Myeloid Leukemia (AML) is a blood cancer that starts in the bone marrow, where blood cells are made. It causes the marrow to produce large numbers of immature myeloid cells that do not function normally. These abnormal cells accumulate in the marrow and spill into the bloodstream, reducing the production of normal red cells, white cells, and platelets. As the disease advances, the proportion of immature cells, called blasts, increases and can interfere with organ function. Over time, AML may spread to other organs such as the spleen or liver, and the blood counts continue to worsen.
Trial detailsLast updated 19 Nov 2026
Age18+ yearsPhasePhase IVTrial ID2026-526320-44-00Protocol codeCLIN-60340-450Estimated enrolment494 patientsSponsorIpsen Pharma

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.